GENE ONLINE|News &
Opinion
Blog

2023-03-15| Special

Novo Nordisk Announces Major Insulin Price Cut by Up to 75%, Following in the Footsteps of Eli Lilly

by Richard Chau
Share To
Danish drugmaker Novo Nordisk recently announced a reduction in the list price of several insulin drugs in the United States by up to 75%, making it the latest major pharmaceutical company to slash the insulin price amid pressure to curb the treatment costs for diabetics in the country. 

The price change, which will take effect on January 1, 2024, follows a path set earlier this month by Eli Lilly, one of the major rivals of Novo Nordisk in the insulin market of the United States. It involves the company’s pre-filled pens (FlexPen) as well as vials of long- and short-acting insulins, including Levemir, Novolin, NovoLog and NovoLog Mix70/30. 

The list prices for Levemir and Novolin vials and FlexPens will be reduced by 65%, while NovoLog and NovoLog Mix 70/30 will become 75% cheaper. The list prices of unbranded insulin products will also be reduced to match lowered prices of respective branded insulin products.

GO Prime with only $1.49 now

LATEST
Eli Lilly’s Tirzepatide Gets Approval in China for Weight Loss Management
2024-07-22
Roche Reports Positive Clinical Trial Results for Two Diabetes-Related Eye Disease Therapies
2024-07-19
7th Person in History Possibly Cured From HIV After Stem Cell Transplant for Acute Myeloid Leukemia
2024-07-19
Large RCT Finds Time-Lapse Imaging for Embryo Selection in IVF Does Not Improve Live Birth Rates
2024-07-19
Assessment of Supply Chain Risk Key to Improving Medicine Access
2024-07-18
SK Biopharma and Full-Life Sign US$571.5 Million Deal for Innovative Radiopharmaceutical FL-091
2024-07-18
Autoimmune Patients See Breakthrough Response to Allogeneic CD19-Targeted CAR-T Therapy
2024-07-18
EVENT
Scroll to Top